JAHA:静脉血栓栓塞患者出血并发症的危险分层!

2018-03-07 xing.T MedSci原创

由此可见,HAS-BLED评分对VTE患者出血风险有较好的预测效度。癌症作为一个独立的出血危险因素值得考虑。

高血压、肝肾功能异常、卒中、出血、不稳定的国际标准化比值(INR)、老年人、药物或酒精使用(HAS-BLED)评分对大出血并发症有很强的预测价值,但在静脉血栓栓塞(VTE)患者中只进行了有限地验证。近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,这项研究评估了大量VTE患者的HAS-BLED评分。

研究人员通过保险索赔数据库确定了在2010年1月1日至2013年11月31日之间初步诊断为VTE的年龄≥18岁成人组成的回顾性队列。病人被追踪到死亡、任何出血事件或研究结束。通过比例风险模型评估HAS-BLED评分以及组分。分别为30、60、90和180天报告了累积的发病率。

研究人员确定了132280例VTE患者,73.8%的患者HAS-BLED评分为0-2分,3.6%的患者HAS-BLED评分≥4分,以及有4789例出血事件(占3.6%)。HAS-BLED评分每增加1分导致出血率增加20%至30%,但在癌症队列中仅从3增加4分时才与所有出血(csHR=1.41,95%可信区间:1.17-1.69;sdHR=1.40,95%可信区间:1.17-1.69)和大出血(csHR=1.66,95%可信区间:1.26-2.20;sdHR=1.66,95%可信区间:1.25-2.19)显著相关。将癌症作为一个独立的变量加入到大出血模型是所有变量中提供了最强的相关性csHR=2.25(95%可信区间:1.98-2.56)和sdHR=2.11(95%可信区间:1.85-2.41)。

由此可见,HAS-BLED评分对VTE患者出血风险有较好的预测效度。癌症作为一个独立的出血危险因素值得考虑。

原始出处:


Joshua D. Brown,et al. Risk Stratification for Bleeding Complications in Patients With Venous Thromboembolism: Application of the HAS‐BLED Bleeding Score During the First 6 Months of Anticoagulant Treatment.JAHA.2018. https://doi.org/10.1161/JAHA.117.007901

本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757954, encodeId=c8e21e57954c5, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Sep 29 06:29:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720518, encodeId=67031e20518d5, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Tue Oct 09 07:29:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697657, encodeId=f672169e6579b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jun 10 20:29:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955351, encodeId=ad3a195535189, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Sep 17 14:29:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267757, encodeId=b8c7126e757f5, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 09 09:29:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293911, encodeId=76592939112a, content=不错哦.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Mar 07 19:12:52 CST 2018, time=2018-03-07, status=1, ipAttribution=)]
    2018-09-29 仁医06
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757954, encodeId=c8e21e57954c5, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Sep 29 06:29:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720518, encodeId=67031e20518d5, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Tue Oct 09 07:29:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697657, encodeId=f672169e6579b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jun 10 20:29:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955351, encodeId=ad3a195535189, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Sep 17 14:29:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267757, encodeId=b8c7126e757f5, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 09 09:29:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293911, encodeId=76592939112a, content=不错哦.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Mar 07 19:12:52 CST 2018, time=2018-03-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757954, encodeId=c8e21e57954c5, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Sep 29 06:29:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720518, encodeId=67031e20518d5, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Tue Oct 09 07:29:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697657, encodeId=f672169e6579b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jun 10 20:29:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955351, encodeId=ad3a195535189, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Sep 17 14:29:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267757, encodeId=b8c7126e757f5, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 09 09:29:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293911, encodeId=76592939112a, content=不错哦.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Mar 07 19:12:52 CST 2018, time=2018-03-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1757954, encodeId=c8e21e57954c5, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Sep 29 06:29:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720518, encodeId=67031e20518d5, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Tue Oct 09 07:29:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697657, encodeId=f672169e6579b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jun 10 20:29:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955351, encodeId=ad3a195535189, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Sep 17 14:29:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267757, encodeId=b8c7126e757f5, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 09 09:29:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293911, encodeId=76592939112a, content=不错哦.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Mar 07 19:12:52 CST 2018, time=2018-03-07, status=1, ipAttribution=)]
    2018-09-17 xue8602
  5. [GetPortalCommentsPageByObjectIdResponse(id=1757954, encodeId=c8e21e57954c5, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Sep 29 06:29:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720518, encodeId=67031e20518d5, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Tue Oct 09 07:29:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697657, encodeId=f672169e6579b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jun 10 20:29:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955351, encodeId=ad3a195535189, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Sep 17 14:29:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267757, encodeId=b8c7126e757f5, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 09 09:29:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293911, encodeId=76592939112a, content=不错哦.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Mar 07 19:12:52 CST 2018, time=2018-03-07, status=1, ipAttribution=)]
    2018-03-09 zhaohui6731
  6. [GetPortalCommentsPageByObjectIdResponse(id=1757954, encodeId=c8e21e57954c5, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Sep 29 06:29:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720518, encodeId=67031e20518d5, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Tue Oct 09 07:29:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697657, encodeId=f672169e6579b, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jun 10 20:29:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955351, encodeId=ad3a195535189, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Sep 17 14:29:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267757, encodeId=b8c7126e757f5, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 09 09:29:00 CST 2018, time=2018-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=293911, encodeId=76592939112a, content=不错哦.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Mar 07 19:12:52 CST 2018, time=2018-03-07, status=1, ipAttribution=)]
    2018-03-07 owlhealth

    不错哦.学习了

    0

相关威廉亚洲官网

Neurosurgery:脑出血后早期预防VTE现状调查

深静脉血栓形成(DVT)和肺栓塞(PE)是脑出血患者致死和致残的主要原因。脑出血患者的静脉血栓栓塞(VTE)是缺血性卒中的四倍。脑出血后症状性VTE发生率为1-10%,无症状性VTE为20-80%。

Eur Respir J:无诱因肺栓塞后复发性静脉血栓栓塞的危险因素分析!

在首次无诱因肺栓塞后,肺栓塞的诊断时的年龄、PVOI或抗凝治疗6个月以及抗磷脂抗体阳性被认为是VTE复发的独立预测因子。

BMJ:遗传性血栓形成倾向孕妇如何降低首次VTE风险?

有研究表明,与年龄匹配的对照组相比,妊娠使得女性VTE的风险增加了5~6倍。遗传性血栓形成倾向使妊娠相关VTE的风险增加34倍。2017年10月,发表在《BMJ》的一项由荷兰科学家进行的系统回顾和贝叶斯Meta分析,考察了妊娠女性的血栓形成倾向以及首次VTE风险。

Thromb Haemost:癌症相关VTE:威廉亚洲博彩公司 推荐的LMWH治疗真能改善临床结局?

发表在《Thromb Haemost》的一项由荷兰科学家进行的观察性研究,考察了维生素K拮抗剂(VKA)与低分子量肝素(LMWH)治疗癌症相关静脉血栓栓塞(VTE)在常规临床实践中结局。

J Thromb Haemost:轻度抗凝血酶缺乏症与复发性静脉血栓栓塞风险!

由此可见,该研究证实了轻度抗凝血酶缺乏是复发性VTE的危险因素。

J Thromb Haemost:瓜氨酸化组蛋白H3可预测癌症患者静脉血栓栓塞的风险!

由此可见,这些数据表明NET的生物标志物与癌症患者VTE的发生有关,这提示NET在癌症相关血栓形成中发挥着重要作用。